Skip to main content
Premium Trial:

Request an Annual Quote

FDA to Use GVKBio’s Biomarker DB in Voluntary Exploratory Data Program

NEW YORK (GenomeWeb News) - GVK Biosciences today said it has inked an agreement that will give the US Food and Drug Administration access to the company’s Clinical Biomarker Database.
 
Under the agreement, the FDA will use the database as part of its Voluntary Exploratory Data Submission Program and in internal research projects.
 
The database holds information from published literature relating to clinical and pre-clinical biomarkers, and may be used in biomarker design and validation research, the company said.
 
GVK Bio, which is headquartered in Hyderabad, India, has a US base in Columbia, Md.
 
Financial terms of the agreement were not released.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.